WASHINGTON — President Trump’s Rose Garden speech on drug prices is over. The media blitz that initially animated his top health lieutenants is fading. Now the administration has to take action.
Overwhelmingly, the bulk of the Trump administration plan to bring down drug prices — to force companies to include a medication’s price in their TV commercials or expand the way pharmacy benefit managers negotiate prices for costly cancer treatments, for example — falls under the authority of Health and Human Services Department and two of its most prominent agencies, the Food and Drug Administration and the Centers for Medicare and Medicaid Services.
About the Author Reprints
